Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  stage III papillary thyroid cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-12 of 12 for your search:
Start Over
Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1532C00065, NCI-2013-01983, EudraCT 2013-000423-14, NCT01843062
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Pasireotide and Everolimus in Treating Patients with Thyroid Cancer Refractory to Radioiodine
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI1777-09, NCI-2011-03377, CSOM230CUS18T, IRB00041909, WCI-1777, NCT01270321
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Dabrafenib with or without Trametinib in Treating Patients with Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12064, NCI-2012-01700, 2012C0074, NCCNGSK20008, NCT01723202
Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 21 to 70
Trial IDs: UW13115, NCI-2014-00833, 2014-0391, 2014-0391-CP002, NCT02138214
Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KO-TIP-001, NCI-2015-01835, NCI-2015-00949, NCT02383927
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 2015-002067-41, NCT02628067
Dabrafenib and Radioactive Iodine in Treating Patients With Papillary Thyroid Carcinoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-337, NCI-2012-00817, NCT01534897
Vemurafenib and Iodine I 131 in Treating Patients with BRAF Mutant, Radioiodine-Refractory Thyroid Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 14-031, NCI-2014-01210, NCT02145143
Start Over